Working... Menu

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01825928
Recruitment Status : Completed
First Posted : April 8, 2013
Last Update Posted : July 13, 2017
Information provided by (Responsible Party):
Wei Hao, Central South University

Brief Summary:
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. paliperidone are Second generation antipsychotics,and have effects of blocking dopamine2(D2) and 5-hydroxytryptamine 2A(5-HT) receptors neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among methamphetamine addicts.

Condition or disease Intervention/treatment Phase
Methamphetamine Dependence Drug: Paliperidone Drug: placebo Not Applicable

Detailed Description:
Methods:A Multiple-Center, Randomized, Double-Blind.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Trial of Paliperidone Extended-Release Tablets for The Treatment of Methamphetamine Dependence in Chinese Patients After Detoxification
Study Start Date : February 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Experimental: paliperidone
paliperidone arm,3mg/pill,3mg/day.last84 days.
Drug: Paliperidone
Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
Other Names:
  • Paliperidone Extended-Release Tablets
  • Invega

Placebo Comparator: placebo
placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
Drug: placebo
placebo group,3mg/pill,3mg/day forced titration method,last 84 days

Primary Outcome Measures :
  1. Abstinent time of Methamphetamine addict [ Time Frame: up to 84 days ]
    The outcome was the confirmed abstinence during 12 weeks. Confirmed abstinence was defined as a negative urine drug test. The following aggregate measures of urine drug test results were calculated: the time-to-first positive urine test, the Treatment Effectiveness Score (TES; the sum of the number of METH-free urine samples submitted per participant ), the longest period of MA abstinence during the 84 days.

Secondary Outcome Measures :
  1. Time (day) to first psychosis relapse from baseline to 84 days [ Time Frame: up to 84 days ]
    psychosis assessement was made once a week.Psychotic symptom relapse was defined as one or more of the following: (1) hospitalization for psychotic symptoms; deliberate self-injury or violent behavior, or suicidal or homicidal ideation that was clinically significant;25% increase in PANSS total score;for patients who scored >40 at randomization, or a 10-point increase for patients who scored ≤40 at randomization for two consecutive assessments (within 1 week), and (4) increase in prespecified individual PANSS items scores (P1, P2, P3, P6, P7 and G8) to ≥5 for patients whose score was ≤3 at randomization, or to ≥6 for patients whose score was 4 at randomization for two consecutive assessments (within 1 week)

  2. Change from baseline in CGI-S scores at 84 days [ Time Frame: up to 84 days ]
    general condition assessment was made by CGI-S once a week, and calculated the total scores

  3. Change from baseline in Visual Analogue Scale (VAS) at 84 days [ Time Frame: up to 84 days ]
    Methamphetamine craving assessment was made by VAS once a week, and calculated the total scores

  4. number of treatment day which calculated from randomization to the last visiting point [ Time Frame: up to 84 days ]
    record the follow up time

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged 18 years to 60 years
  • Met the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria for METH dependence with psychosis
  • Completing inpatient METH detoxification (≤30 days) with psychotic symptoms disappeared
  • Beoff any anti-psychotic medication for 7 days after discharging from hospital were enrolled at clinical site
  • Participants were interesting in reducing or stopping METH use
  • Every patient also had a significant other (eg., spouse or relative) who supervised their compliance with the visit schedule and study procedures
  • Women of childbearing potential agreed to use contraception during the study.

Exclusion criteria:

  • Pregnancy or breastfeeding;
  • Significant medical conditions (eg., acute renal failure, endocarditis, and tuberculosis); hepatic failure; past or present history of an AIDS-indicator disease; active hepatitis or aspartate amino transferase or alanine aminotransferase more than three times the upper limit of normal
  • Known intolerance or hypersensitivity to paliperidone ER; other psychosis; present dependence on substances other than METH or poly-substance abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01825928

Layout table for location information
China, Hunan
The Second Xiangya Hospital of Central University
Changsha, Hunan, China, 410011
Sponsors and Collaborators
Wei Hao
Layout table for investigator information
Study Director: Wei Hao, MD., Ph.D. Central South University

Layout table for additonal information
Responsible Party: Wei Hao, The Second Xiangya Hospital of Cental South University, Central South University Identifier: NCT01825928     History of Changes
Other Study ID Numbers: 100000-068944
First Posted: April 8, 2013    Key Record Dates
Last Update Posted: July 13, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Wei Hao, Central South University:

Additional relevant MeSH terms:
Layout table for MeSH terms
Paliperidone Palmitate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Central Nervous System Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors